TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Gary Musso, PhD
President at Musso and Associates LLC

Profile

Dr. Musso is President of Musso and Associates LLC, a consulting company providing CMC technical, regulatory and compliance services. Dr. Musso received his Ph.D. in 1984 from the University of Chicago. He has worked for 35 years in the biotech industry with major leadership roles in two approved oncology drugs; VP Operation at Proteolix/Onyx (Kyprolis®- multiple myeloma) and  VP Development at Praecis (Plenaxis®- prostate cancer).  He has also had significant contributions to the following approved products: Vyleesi®, Angiomax®, Tymlos®, and Trulance®.  In 2005, Dr. Musso started Musso and Associates LLC and has worked with over 80 companies to support development programs and M&A activities.  His scientific interests are in peptides, small molecule drugs, and sophisticated drug delivery systems. Assisting smaller organizations and research institutes with effective strategies and efficient drug development processes are the focus of his company's efforts.

Gary Musso, PhD's Network

Agenda Sessions

  • CMC Technical and Regulatory Strategies for Development of Peptides and Oligonucleotides

    , 13:55